The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
This trial is active, not recruiting.
|Start date||June 2008|
|End date||April 2014|
|Trial size||20 participants|
|Trial identifier||NCT00722722, 08-000556|
Patients planning to have kidney transplantation who are sensitized to their donors have high levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney transplant recipients at risk for rejection very early after transplant. This study is trying to determine if the drug bortezomib (Velcade ™) can reduce donor specific alloantibodies to a level that permits kidney transplantation without a high risk for rejection.
|Intervention model||single group assignment|
A 50% reduction in anti-HLA antibody production by bone marrow derived ASC isolated from sensitized renal allograft candidates treated with bortezomib monotherapy in vivo.
time frame: 6 months
Male or female participants at least 18 years old.
Inclusion Criteria: - Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. - Female subject is post-menopausal, surgically sterilized, or she and/or sexual partner are willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. - Male subject agrees to use an acceptable method for contraception for the duration of the study. - Renal transplant candidates who otherwise meet our acceptance criteria. - Evidence of alloantibody in their serum (panel reactive antibody >20% and specificities determined by single antigen flow bead assay. - Sensitized patients with no living donors or have donor-specific antibody levels too high to undergo successful transplantation using our current protocols (T or B cell crossmatch channel shift >500). Exclusion Criteria: - Patient has a platelet count of <30 x 109/L within 14 days before enrollment. - Patient has an absolute neutrophil count of ANC<1.0 x 109/L within 14 days before enrollment. - Patient has >Grade 2 peripheral neuropathy within 14 days before enrollment. - Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. - Patient has hypersensitivity to bortezomib, boron or mannitol. - Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. - Patient has received other investigational drugs within14 days before enrollment. - Serious medical or psychiatric illness likely to interfere with participation in this clinical study. - Diagnosed or treated for malignancy within 5 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy. - Contraindication to kidney transplantation—active infection, comorbid medical conditions, etc.
|Official title||The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates|
|Principal investigator||Mark D. Stegall, M.D.|
|Description||The study is designed to assess the impact of in vivo treatment of bortezomib on anti-HLA production by normal antibody secreting cells (ASC) in sensitized renal allograft candidates. The design involves in vivo treatment with bortezomib for one 4 dose cycle (days 1, 4, 8 and 11). Using novel assays, anti-HLA production is determined by bone marrow derived ASC at baseline (prior to therapy) and after treatment (at day 14, 3 days after the last bortezomib dose). Paired data are used with patients serving as their own controls. Finally, the safety of bortezomib is evaluated by monitoring total serum antibody levels and the incidence of side effects (primarily neuropathy) at 1 month, the final follow-up point.|
Call for more information